Insider Cluster (3 insiders) ·Filed Feb 23, 2026

IRWD

IRONWOOD PHARMACEUTICALS INC
BEARISH
Impact 6/10
Horizondays Processed7mo ago
Insider cluster: 3 insiders, $0.5M total
Actionable Insight ▼ Bearish

Traders should monitor for downward pressure on IRWD shares, especially if this selling continues into next quarter. Absent offsetting positive fundamentals or news, this level of coordinated C-suite selling may signal lack of confidence in near-term valuation or upcoming catalysts.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
IRWD ▼ -6.67% at T+60d
SHORT call ✓ call won +6.67% · α vs SPY +14.92% · entry $3.75 → $3.50
Entry anchored
Feb 20, 03:59 PM ET
via exchange tick
T+1d
+1.07%
call -1.07% · α -0.33%
$3.79
settled 7mo ago
T+5d
-4.80%
call +4.80% · α +5.42%
$3.57
settled 7mo ago
T+20d
-12.27%
call +12.27% · α +8.32%
$3.29
settled 7mo ago
T+60d
-6.67%
call +6.67% · α +14.92%
$3.50
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

Six open-market share sales by three C-suite executives at Ironwood Pharmaceuticals (IRWD) over the past seven days totaled approximately $958,000. The CEO, CFO, and Chief Legal Officer collectively sold over 237,000 shares at prices between $3.66 and $3.81 per share, indicating coordinated insider selling.

Key Financial Metrics

Direction
selling
Total Value
$958.0K
Insiders
3

Key Facts

  • CEO Thomas McCourt sold 198,283 shares for $739,929.33 over two days (Feb 23–24, 2026).
  • CFO Gregory Martini sold 21,944 shares for $81,888.09.
  • Chief Legal Officer John Minardo sold 36,492 shares for $136,176.57.
  • All transactions were open-market sales (Form 4 'S' codes), not related to grants, taxes, or derivatives.
  • Total insider selling cluster value: $958,000 over 7 days, consistent with recent 30-day trend.

Financial Impact

$958,000 in net insider selling by C-suite executives over 7 days

insider ownershipinvestor sentimentpotential dilution signal

Risk Factors

  • Insider selling could accelerate if quarterly results disappoint.
  • Perception of weakening fundamentals despite no public negative news yet.
  • Potential for increased short interest following this cluster.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (6 trades, 7d window)cluster-IRWD-1772109092031
6 reports for IRWD
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+20▲ +12.27%Feb 23, 2026
Filters
Rows
Reports for IRWD — sortable, filterable
TypeNow
Aug 6, 2026
8w ago
8-K
BULLISH ★ 7/10
$4.26 $4.29▲ +0.70%▲ +0.10%$3.62 (−15.02%)
May 13, 2026
20w ago
8-K
MIXED ★ 6/10
$3.68 $3.63▼ −1.36%▼ −0.75%$3.62 (−1.63%)
May 7, 2026
21w ago
8-K
BULLISH ★ 7/10
$4.17 $3.24▼ −22.30%▼ −25.44%$3.62 (−13.19%)
Feb 25, 2026
31w ago
8-K
BEARISH ★ 5/10
$3.36 $3.19▲ +5.06%▼ −0.18%$3.62 (−7.74%)
Feb 23, 2026
31w ago
Insider Cluster
BEARISH ★ 6/10
$3.75 $3.29▲ +12.27%▲ +8.32%$3.62 (+3.47%)
Feb 23, 2026
31w ago
Insider Cluster
BEARISH ★ 7/10
$3.75 $3.29▲ +12.27%▲ +8.32%$3.62 (+3.47%)
Showing 6 of 6

US Market Status

Market Open — Closes in 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Feb 26, 2026